In Merck's study, its vaccine, Vaxneuvance, met key immunogenicity and safety endpoints for healthy infants aged 2-15 months, and its safety profile was similar to that of PCV13 after each vaccine dose. Vaxneuvance was found to be noninferior to PCV13 for all 13 shared serotypes at 30 days after the third dose based on serotype-specific response rates. On the basis of serotype-specific immunoglobulin G geometric mean concentrations, it was also noninferior to 12 of the 13 shared serotypes. After the fourth dose at 30 days, similar findings were reported.
Learn more about PCV15.
This Rapid Recent Study Quiz was excerpted and adapted from the Medscape articles: pneumococcal vaccine 15-valent, pneumococcal vaccine 20-valent, Community-Acquired Pneumonia (CAP), Antimicrobials: When 'Short Courses' Are Enough, CDC Issues New Pneumococcal Vaccine Recommendations for Adults, Real-World Corticosteroid Use in Severe Pneumonia, 15-Valent Pneumococcal Vaccine Shows Noninferiority to 13-Valent Vaccine in Infants, Narrow-Spectrum Antibiotics Appear Effective and Safe for Community Acquired Pneumonia, amoxicillin, and Pediatric Community Acquired Pneumonia: Lower Amoxicillin Dose and Shorter Duration May Be Effective.
Lead image: Science Source
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Stuart Bronze. Rapid Review Quiz: Pneumococcal Infections - Medscape - Mar 11, 2022.